- Home
- ADN vs CHRO Comparison
ADN vs CHRO Comparison
Compare ADN & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- CHRO
- Stock Information
- Founded
- ADN 2006
- CHRO 2002
- Country
- ADN United States
- CHRO United States
- Employees
- ADN N/A
- CHRO N/A
- Industry
- ADN Power Generation
- CHRO
- Sector
- ADN Utilities
- CHRO
- Exchange
- ADN Nasdaq
- CHRO Nasdaq
- Market Cap
- ADN 6.6M
- CHRO 7.6M
- IPO Year
- ADN N/A
- CHRO 2024
- Fundamental
- Price
- ADN $2.10
- CHRO $1.35
- Analyst Decision
- ADN
- CHRO
- Analyst Count
- ADN 0
- CHRO 0
- Target Price
- ADN N/A
- CHRO N/A
- AVG Volume (30 Days)
- ADN 23.3K
- CHRO 135.3K
- Earning Date
- ADN 08-19-2025
- CHRO 08-12-2025
- Dividend Yield
- ADN N/A
- CHRO N/A
- EPS Growth
- ADN N/A
- CHRO N/A
- EPS
- ADN N/A
- CHRO N/A
- Revenue
- ADN $3,276,000.00
- CHRO N/A
- Revenue This Year
- ADN $6,528.51
- CHRO N/A
- Revenue Next Year
- ADN N/A
- CHRO N/A
- P/E Ratio
- ADN N/A
- CHRO N/A
- Revenue Growth
- ADN 113.28
- CHRO N/A
- 52 Week Low
- ADN $1.71
- CHRO $0.45
- 52 Week High
- ADN $8.79
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- ADN 36.88
- CHRO 63.60
- Support Level
- ADN $2.03
- CHRO $1.12
- Resistance Level
- ADN $2.31
- CHRO $1.23
- Average True Range (ATR)
- ADN 0.18
- CHRO 0.16
- MACD
- ADN -0.04
- CHRO 0.01
- Stochastic Oscillator
- ADN 3.48
- CHRO 30.26
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.